Investigating how a specific protein affects lung cancer development
Official title: The role of translation initiation factor eIF5B in lung cancer pathogenesis
Funded at Ut Southwestern Medical Center · NIH-10883646 · Data updated 2026-11-12
This study is looking at how a specific protein called eIF5B affects another protein, PD-L1, in lung cancer cells, which helps tumors hide from the immune system, and it hopes to find new ways to improve treatment for patients with non-small cell lung cancer who aren't responding to current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project start | July 6, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $452,600 |
| NIH project number | 5R01CA273585-02 |
| Project ID | NIH-10883646 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with non-small cell lung cancer, particularly those who have not responded to current immunotherapy treatments.
✕Less likely to help
Patients with lung cancer who have already benefited from existing immunotherapies or those with other types of cancer may not receive direct benefits from this research.
What this research studies
This research focuses on understanding the role of the translation initiation factor eIF5B in lung cancer, particularly how it influences the expression of PD-L1, a protein that helps tumors evade the immune system. By using advanced CRISPR-based screening techniques, the study aims to identify the mechanisms that regulate PD-L1 levels in lung cancer cells. The findings could reveal new therapeutic targets for improving treatment outcomes in patients with non-small cell lung cancer, especially those who do not respond to existing immunotherapies.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that enhance the effectiveness of immunotherapy for lung cancer patients.
How similar studies have gone: Previous research has shown promising results in targeting immune checkpoints in cancer, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
-
Ut Southwestern Medical Center
Dallas, United States Active
Researchers
- Principal investigator: O'donnell, Kathryn Ann — Ut Southwestern Medical Center
- Study coordinator: O'donnell, Kathryn Ann
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.